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Background: Despite a substantial reduction in virological failures following introduction of new potent antiretroviral
therapies in the latest years, drug resistance remains a limitation for the control of HIV-1 infection. We evaluated trends
and correlates of resistance in treatment failing patients in a comprehensive database over a time period of relevant
changes in prescription attitudes and treatment guidelines.
Methods: We analyzed 6,796 HIV-1 pol sequences from 49 centres stored in the Italian ARCA database during the
2003–2012 period. Patients (n = 5,246) with viremia > 200 copies/mL received a genotypic test while on treatment.
Mutations were identified from IAS-USA 2013 tables. Class resistance was evaluated according to antiretroviral regimens
in use at failure. Time trends and correlates of resistance were analyzed by Cochran-Armitage test and logistic
regression models.
Results: The use of NRTI backbone regimens slightly decreased from 99.7% in 2003–2004 to 97.4% in 2010–2012.
NNRTI-based combinations dropped from 46.7% to 24.1%. PI-containing regimens rose from 56.6% to 81.7%, with an
increase of boosted PI from 36.5% to 68.9% overtime. In the same reference periods, Resistance to NRTIs, NNRTIs and
PIs declined from 79.1% to 40.8%, from 77.8% to 53.8% and from 59.8% to 18.9%, respectively (p < .0001 for all
comparisons). Dual NRTI + NNRTI and NRTI + PI resistance decreased from 56.4% to 33.3% and from 36.1% to 10.5%,
respectively. Reduced risk of resistance over time periods was confirmed by a multivariate analysis.
Conclusions: Mutations associated with NRTIs, NNRTIs and PIs at treatment failure declined overtime regardless of
specific class combinations and epidemiological characteristics of treated population. This is likely due to the
improvement of HIV treatment, including both last generation drug combinations and prescription guidelines.
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Despite substantial reductions in AIDS-related morbidity
and mortality [1,2], advancements in antiretroviral ther-
apy have always been challenged by the development of
drug resistance. Evolution of drug-resistant HIV variants
remains a major limitation for the long-term control of
HIV-1 infection as wide resistance to multiple drug clas-
ses is associated with clinical deterioration and death [3].
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major classes of antiretrovirals in use since the introduc-
tion of the highly active aniretroviral treatment (HAART):
nucleos(t)ide reverse-transcriptase inhibitors (NRTIs),
non-nucleoside reverse-transcriptase inhibitors (NNRTIs)
and protease inhibitors (PIs) [4]. The prevalence of resist-
ant strains rose to high levels in high-income countries in
the past, when treatment often made of suboptimal regi-
mens became available [5-8]. Drug resistance has emerged
recently also in low/middle-income countries, as a conse-
quence of the growing access to first- generation drug
combinations coupled with the high burden of HIV infec-
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of the transmission of resistant strains [11] which may
compromise the efficacy of combination antiretroviral
treatment (cART) in drug-naive patients [12]. Neverthe-
less, when the initial cART is tailored to the viral genotype
to ensure full activity, patients can achieve virological re-
sponses comparable to those harbouring wild type virus
[13]. Therefore, it is expected that current optimal regi-
mens, selected on the basis of HIV pol genotype, control
viral replication even in patients with primary resistance.
Available results on the prevalence of drug resistance
are often difficult to compare as they differ in resistance
associated mutations taken into account, timing of sam-
ples and selection of study populations. The latter could
vary from all subjects on antiretroviral treatment, to pa-
tients failing ART, to subjects with available resistance
test results. Moreover, these studies have estimated the
prevalence of HIV drug resistance using a variety of ana-
lytical methods resulting in a wide range of estimates,
ranging from 50% to 80% of subjects failing an antiretro-
viral treatment [5-8,14-16].
A reduction of acquired resistance has been recently
reported in Italy until 2009 [17,18]. This may have de-
rived from the latest prescription attitudes and, likely,
to the introduction of more potent new drugs in sal-
vage therapies. Nevertheless, considerable proportions
of treated individuals are still likely to select for resist-
ance mutations while on antiretroviral treatment, which
may result in an ongoing transmission of HIV-1 resistant
variants.
The aim of this study was to monitor acquired resist-
ance to understand present trends and correlates of class
resistance in subjects failing cART regimens in a multi-
center Italian network based over the 2003–2012 period.
Previous reports considered resistance prevalence among
the whole studied population, regardless of the regimen
administered at the time of resistance testing [16-18].
Since treatment changes can influence drug pressure on
previously selected virus variants, we chose instead to
evaluate resistance trends according to the antiretroviral
drugs taken at time of failure.
Patients and methods
Patients
Patients included in the study were adult HIV-infected
individuals enrolled in 49 Italian clinical centres during
the 2003–2012 period. All the clinical centres contributed
data to the Antiretroviral Resistance Cohort Analysis
(ARCA, www.hivarca.net) database, a nationwide reposi-
tory used for non-profit research purposes and stored on
a central server. Written informed consents had been ob-
tained by patients. The research did not require approval
from the Ethics Committees, according to the Italian law
at the time when the study was conducted, since it wasperformed as an observational study in the context of clin-
ical routines (art.1, Low. Decree 211/2003).
Inclusion criteria
Cases were selected according to DHHS Guidelines [19]
on the basis of the concomitant detection of HIV-1 viral
load over 200 copies/ml after at least 6 months of on-
going therapy and the availability of an HIV-1 genotypic
test obtained while on treatment. The cART regimen
was defined as any combination of three or more drugs
including an NNRTI and/or a PI. When more than one
sequence was available from the same subject in the
same year of study, the first sequence was considered.
HIV-1 genotype and class resistance evaluation
Genotyping was based on a partial HIV-1 pol sequence in-
cluding RT and protease and ranging from 1,000 to 1,280
nucleotides, depending on the sequencing protocol used at
the contributing laboratory. Emergence of resistance at
failure was evaluated according to the latest International
AIDS Society (IAS) mutation list [20]. Any thymidine
analogue mutations (TAMs) (M41L, D67N, K70R, L210W,
T215Y/F and K219Q/E), K65R, L74I/V, Y115F, Q151M,
69ins, M184I/V, any major NNRTI mutation (L100I, K101P,
K103N/S, V106A/M, V108I, Y181C/I, Y188C/H/L, G190A/S,
P225H, M230L) and the presence of major PI mutations
(D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54L/M,
Q58E, L76V, V82A/F/L/S/T, I84V, N88D/S, L90M) were
considered. TAMs were classified according to different pat-
terns in profile 1 (M41L, L210W and T215Y) and profile 2
(D67N, K70R, T215F, K219Q/E). Specifically, only mutations
related to drug in use at genotype were taken into account.
NRTI, NNRTI and PI class resistance was evaluated ac-
cording to NRTI, NNRTI or PI based treatment used at
time of virological failure.
Four periods of study were evaluated encompassing
years 2003–2004, 2005–2006, 2007–2009 and 2010–2012.
Subtype was assigned using the NCBI HIV-1 subtyping
tool.
Statistical analysis
The Cochrane-Armitage test was used to evaluate tem-
poral trends. The crude and Mantel-Haenszel adjusted
odds ratios (OR) of class resistance detection with 95%
confidence interval (CI) were calculated. Univariate ana-
lysis was performed using χ2 and logistic regression. A
subsequent multivariate analysis was done on all vari-
ables, using the same tests with a full model. Analyses
were done with SAS Software version 9.1.
Results
Characteristics of the population
The sequences were obtained from 5,246 HIV-1 positive
individuals. Overall, male to female ratio was 2.1 (3,554/
Figure 1 Trends in drug class usage and resistance at failure.
Part A: Distribution of antiretroviral classes in use at time of genotyping
when HIV-RNA > 1 Log copies/ml: trends of use are shown for
nucleoside reverse-transcriptase inhibitors (NRTI, p < .0001*), non
nucleoside reverse-transcriptase inhibitors (NNRTI, p < .0001*), protease
inhibitors (PI, p < .0001*), Boosted PI (p < .0001*), antiretroviral regimens
combining NRTI + NNRTI (p < .0001*), NRTI + PI (p < .0001*), NRTI +
NNRTI + PI (p < .0001*). Part B: Prevalence of drug class resistance
during the study period: trends of resistance are shown for NRTI
(p < .0001*), NNRTI (p < .0001*), PI (p < .0001*), Boosted PI (p < .0001*),
antiretroviral regimens combining NRTI + NNRTI (p < .0001*), NRTI + PI
(p < .0001*), NRTI + NNRTI + PI (n.s.*). * Cochrane-Armitage test
for trends.
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(IDU) for 35.4% (n = 1,858), heterosexual sex in 33.5%
(n = 1,757), and men having sex with men (MSM) were
16.7% (n = 876) of the study population. Non-B subtypes
were detected in 9.1% of the subjects included in the
study (n = 477). For 4,130 (78.7%) patients a single pol
sequence was available for the analysis. Two, 3, 4 and
more than 4 sequences were collected for 800, 227, 65,
24 subjects (15.2%, 4.3%, 1.2%, 0.5% respectively).
The study included 6,796 pol sequences from subjects
with viral load above 200 copies/ml while on treatment
in the 2003–2012 period. Their distribution was as fol-
lows: 2,450 in 2003–2004 (36.1%); 2,050 in 2005–2006
(30.2%); 1,641 in 2007–2009 (24.2%); 655 in 2010–2012
(9.6%). Median age of patients at time of genotyping was
42 years (Interquartile ratio, IQR 38–47). Median HIV-
RNA viral load was 4.06 Log copies/ml (IQR 3.36-4.74)
and median CD4 number was 282 cells/μl (IQR 168–429
cells/μl). The median number of previous treatments
experienced by enrolled subjects was 5 for each patient
(IQR 2–9).
Patients’ treatment at time of genotypic test
At genotypic testing 99.4% (n = 6,757), 37.4% (n = 2,539)
and 67.5% (n = 4,589) sequences were obtained from
NRTI-, NNRTI- or PI-treated patients, respectively. HAART
combination included NRTIs +NNRTI in 32.5% (n = 2,207),
NRTIs + PI(s) in 62.6% (n = 4,257), NRTI(s) + PI +NNRTI
in 4.3% (n = 293), an NNRTI + PI(s) in 0.6% (n = 39).
NRTI usage significantly decreased overtime, ranging from
99.7% in 2003–2004 to 97.4% in 2010–2012 (p < .0001).
NNRTI-based regimens decreased from 46.7% to 24.1%
(p < .0001), while an increase of cART regimens including
PIs was observed (from 59.6%, to 81.7%, p < .0001) over-
time. The same increasing trend was confirmed for ritona-
vir boosted PI regimens (from 36.5%, to 68.9%, p < .0001).
Antiretroviral classes were administered in several com-
binations during the study period: the prevalence of the as-
sociation of NRTIs +NNRTI decreased from 40.4% to
18.3% (p < .0001), while combinations of NRTIs + PI(s) in-
creased from 53.4%, to 75.9% (p < .0001). The combination
of all the three classes showed a significant declining trend
from 6.0% to 3.2% (p < .0001) (Figure 1, Part A). The asso-
ciation between an NNRTI and a PI(s) increased signifi-
cantly from 0.3% to 2.6% (p < .0001) in the study period.
Substantial variations were found in the prevalence of
use of some single NRTI agents at failure. A decrease
was observed for thymidine analogues (TA), didanosine
(ddI) and lamivudine (3TC); their use went from 63.0%
to 16.0% (p < .0001), from 36.6% to 1.7% (p < .0001) and
from 63.0%, to 35.6%, (p < .0001), respectively. An op-
posite trend was observed for tenofovir (TDF) from
28.7%, to 63.4% (p < .0001), abacavir (ABC) from 8.9% to
16.6% (p < .0001) and emtricitabine (FTC) from 0% to57.7% (p < .0001). Regarding NNRTIs, a decrease of both
nevirapine (NVP) and efavirenz (EFV) use was detected
at failure; their use went from 24.1% to 7.0% (p < .0001)
and from 22.6% to 12.5% (p < .0001), respectively.
Among subjects assuming an NNRTI, the rate of sub-
jects in treatment regimens including NVP decreased
from 51.6% to 29.1% (p < .0001). Among PIs, significant
reductions in usage frequency at failure were observed
for indinavir (from 6.2% to 0.3%, p < .0001), nelfinavir
(from 17.7% to 0.0%, p < .0001), and saquinavir (from
6.2% to 1.7%, p < .0001). In contrast, an increasing trend
was observed for lopinavir (from 25.0% to 28.1%, p = .012),
fosamprenavir (from 0% to 7.0%, p < .0001), atazanavir
(from 2.3% to 23.8%, p < .0001), darunavir (from 0%
to 16.3%, p < .0001), and tipranavir (from 0.6% to 1.6%,
p < .0001).
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Resistance to NRTIs declined from 79.1% to 40.8%, from
2003–2004 to 2010–2012 (p < .0001). A decreasing trend
was also found for NNRTI mutations, which dropped from
77.8% to 53.8% (p < .0001). PI mutations decreased from
59.8% to 18.9% (p < .0001). Among subjects assuming
NRTIs combined with an NNRTI, resistance to both clas-
ses went from 56.4% to 33.3% (p < .0001); resistance to
NRTI + PI went from 36.1% to 10.5% (p < .0001). Triple
class resistance did not significantly vary overtime in sub-
jects assuming NRTI(s) + NNRTI + PI, ranging from 54.8%
to 42.9% in the study period (Figure 1, Part B).
Declining rates of TA-mutations were found in TA-
containing regimens from 55.3% (853/1543) to 7.62% (8/
105) (p = <.0001). A significant decline was observed for
both TAM1 and TAM2 profiles, ranging from 30.4%
(469/1543) to 3.8% (4/105) (p < .0001) and from 19.6%
(302/1543) to 1.9% (2/105) (p < .0001), respectively. The
K65R mutation went from 4.1% (101/2438) to 2.2%
(14/637) (p = 0.0071) in regimens based on TDF, ddI, stav-
udine and/or ABC. The M184I/V mutations dropped from
67.3% (1131/1680) to 34.1% (211/618) (p < .0001) in pa-
tients on 3TC-, FTC,- or ABC-containing regimens. This
mutation was more common in subjects assuming 3TC
rather than FTC (61.3% vs. 41.6%, p = 0.001). Among sub-
jects failing ABC- or ddI-including cART, the L74V muta-
tion decreased from 16.5% (165/1000) to 3.3% (4/120)
(p < .0001).
Frequencies of specific mutations and resistance patterns
are shown in Table 1 for NNRTI-and PI- based cART.
Among NNRTI-based treatments, a significant decline
was found for K103N/S, V106A/M, V108I, Y181C/I and
G190S/A. No significant variations were detected for
L100I, 188C/L/H, P225H and M230L. In PI-containing
regimens, a reduction of frequency was found for D30N,
L33F, M46I/L, G48V, L76V, V82A/F/T/S, I84V, N88D/S
and L90M. A significant increase was detected for I50L
and I54L/M. No significant variation was found for V32I,
I47A/V, I50V and Q58E.
Predictors of class resistance
Table 2 shows the uni- and multivariate logistic regres-
sion analysis investigating possible predictors of class re-
sistance development on treatment. NRTI resistance in
patients assuming any drug of this antiretroviral class
was found in association with several independent pre-
dictors, including gender, risk factor, age, HIV-1 subtype,
viral load at failure, previous virological failures, number
of previous antiretroviral regimens, prior exposure to
suboptimal NRTI therapy, associated antiretroviral class
in use at failure and period of study.
Independent predictors of NNRTI resistance in NNRTI-
assuming subjects were gender, viral load at failure, previ-
ous virological failures.Predictors of PI resistance were gender, risk factor, viral
load at failure, previous virological failures, number of
previous antiretroviral regimens, prior exposure to sub-
optimal NRTI therapy, use of TA and period of study. The
usage of boosted rather than unboosted PIs was not asso-
ciated with the risk of evolution on PI resistance.
The risk of resistance to any antiretroviral class was not
influenced by the use of TA-including or sparing regimens
or by the use of FTC rather than 3TC in the multivariate
model, even though a lower prevalence of any NNRTI re-
sistance was found in subjects assuming FTC compared
to 3TC (52.6% vs. 61.2%, p = 0.012).
Discussion
Our data provide a solid evidence of a marked decrease
in the prevalence of class resistance among treated indi-
viduals in Italy, as observed from a retrospective analysis
including 49 clinical centres participating in the ARCA
cohort during the last decade. Studies exploring resistance
trends in European countries have observed an initial de-
crease over the 2005–2008 period [15-18,21]. However,
HIV resistance to antiretrovirals still deserves continuous
monitoring, extending the observation to more recent
years and providing updated understanding of the corre-
lates of resistance.
Differently from previous works [14,15] the design of
our study focused on HIV drug resistance in patients as-
suming the corresponding drugs at the time of failure,
providing a more accurate estimate with respect to using
the whole pre-treated population [16-18]. This approach
was adopted mainly to correct for the large observed
variation in antiretroviral usage over time, specifically
taking into account the antiretroviral regimen in use at
failure.
This analysis allowed to detect a twofold and threefold
decrease in resistance prevalence to NRTIs and PIs, re-
spectively during the 2003–2012 decade. The study pe-
riods included two biennia and two triennia to balance
the distribution of subjects overtime. NNRTI resistance
declined less markedly, from 77.8% to 53.8%. Neverthe-
less, the reduction of NNRTI resistance overtime is more
relevant than that observed in previous studies [18,22]
even though a rapid selection of resistant variants is ob-
served in patients failing NNRTI based regimens [23]. We
observed an important reduction of specific NRTI muta-
tions, such as K65R, L74V, M184V and TAMs in subjects
administered drugs selecting for these mutations. This
decrease may be due to multiple factors including the
introduction of compact dual NRTI formulations and as-
sociation with high genetic barrier boosted PIs. Several
NNRTI mutations did not significantly vary overtime: a
stable rate of selection was observed for L100I, 188C/L/H,
P225H and M230L. A declining prevalence of K103N/S
and Y181C/I overtime may be explained by the reduced
Table 1 Frequencies of major non nucleoside reverse-transcriptase inhibitor (NNRTI) and protease inhibitor (PI)
NNRTIa-mutations
Mutations 2003-2004
(n = 1,143)
% (n)
2005-2006
(n = 799)
% (n)
2007-2009
(n = 439)
% (n)
2010-2012
(n = 158)
% (n)
Pc
L100I 6.65 (76) 8.01 (64) 5.92 (26) 8.86 (14) ns
K103N/S 45.83 (525) 43.30 (346) 31.66 (139) 32.28 (51) <.0001
V106A/M 6.47 (74) 4.51 (36) 3.64 (16) 3.80 (6) .0122
V108I 11.64 (133) 10.64 (85) 10.25 (45) 5.70 (9) .0476
Y181C/I 22.83 (261) 21.78 (174) 15.26 (67) 15.19 (24) .0005
Y188C/H/L 5.34 (61) 6.01 (48) 5.24 (23) 6.96 (11) ns
G190A/S 22.66 (259) 20.78 (166) 13.44 (59) 12.03 (19) <.0001
P225H 5.07 (58) 5.26 (42) 4.10 (18) 4.43 (7) ns
M230L 1.57 (18) 1.38 (11) 1.82 (8) 0.63 (1) ns
PIb-mutations,% (n)
Mutations 2003-2004
(n = 1,461)
% (n)
2005-2006
(n = 1,331)
% (n)
2007-2009
(n = 1,262)
% (n)
2010-2012
(n = 535)
% (n)
Pc
D30N 9.5 (139) 5.9 (79) 2.0 (25) 0.9 (5) <0.0001
V32I 4.8 (70) 5.0 (66) 6.9 (86) 4.1 (22) ns
L33F 13.1 (191) 16.1 (214) 15.5 (196) 6.0 (32) <0.0001
M46I/L 32.6 (477) 32.0 (426) 25.6 (323) 12.1 (65) <0.0001
I47A/V 5.5 (81) 5.1 (68) 5.6 (71) 2.4 (13) ns
G48V 5.3 (77) 4.1 (54) 1.4 (18) 0.4 (2) <0.0001
I50L 0.5 (7) 1.8 (24) 1.9 (24) 1.7 (9) 0.004
I50V 2.0 (29) 2.0 (26) 1.9 (24) 0.9 (5) ns
I54L/M 4.5 (66) 5.9 (78) 9.2 (116) 5.2 (28) 0.010
Q58E 5.9 (87) 9.0 (120) 8.1 (102) 4.9 (26) ns
L76V 3.7 (54) 3.5 (47) 3.2 (40) 1.3 (7) 0.020
V82A/F/T/S 26.9 (393) 27.1 (361) 17.7 (224) 6.4 (34) <0.0001
I84V 13.5 (198) 14.9 (198) 16.0 (202) 5.4 (29) 0.015
N88D/S 8.1 (119) 6.8 (90) 3.4 (43) 2,2 (12) <0.0001
L90M 31.5 (461) 29.8 (397) 20.8 (262) 9.5 (51) <0.0001
NNRTI and PI resistance mutations were evaluated among subjects failing a NNRTI- or a PI-containing regimen, respectively.
aNon nucleoside reverse-transcriptase inhibitor.
bProtease inhibitor.
cCochrane-Armitage test for trends.
ns: not significant.
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mutations [24]. A similar declining trend can be observed
when exploring the variations of specific PI mutations, which
are largely influenced by the different variations in use of
specific PIs overtime. For example, we observed an increase
of I50L and I54L/M, which have been reported to be major
mutations for atazanavir and darunavir, respectively [25].
Several epidemiological correlates were found to have
an impact over the selection of resistance mutations only
for NRTIs and PIs. An increased risk of resistance was
found for sexual routes of transmission (heterosexual
and homosexual) compared to IDU, in agreement withother Italian studies [17,18]. This finding may be ex-
plained by different adherence patterns in these subsets of
patients as the higher rates of resistance among subjects
who acquired the infection through sexual route may be
due to suboptimal, even though intermediate to high, levels
of adherence in this population. By contrast, among IDUs,
very low levels of compliance to medical prescriptions can
lead to an important reduction of drug levels, which may
not result in sufficient drug selective pressure leading to re-
sistance to NRTIs or PIs [22]. We also observed a higher
risk of resistance to each class of antiretrovirals among
males rather than females. This association with gender
Table 2 Predictors of nucleoside reverse-transcriptase inhibitor (NRTI), non-nucleoside reverse-transcriptase inhibitor
(NNRTI) and protease inhibitor (PI) resistance
NRTIa resistance OR (95% CI) NNRTIb resistance OR (95% CI) PIc resistance OR (95% CI)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Gender, Female vs. Male 0.74 (0.66-0.82) 0.67 (0.58-0.77) 0.93 (0.77-1.11) 0.82 (0.68-0.98) 0.62 (0.55-0.70) 0.59 (0.50-0.69)
Risk factor
Intravenous drug use - - - - - -
Men having sex with men 1.17 (0.99-1.38) 1.26 (1.05-1.51) 0.63 (0.49-0.81) 0.84 (0.70-1.03) 1.47 (1.22-1.76) 1.45 (1.18-1.79)
Heterosexual sex 1.01 (0.89-1.14) 1.58 (1.36-1.84) 0.78 (0.63-0.97) 0.94 (0.72-1.27) 1.01 (0.88-1.17) 1.61 (1.36-1.91)
Otherd 0.87 (0.75-1.01) 1.68 (1.40-2.01) 0.61 (0.47-0.79) 0.89 (0.64-1.23) 0.89 (0.75-1.06) 1.53 (1.26-1.87)
Age, per 10 years older 1.17 (1.10-1.25) 1.09 (1.01-1.17) 0.93 (0.84-1.03) 0.96 (0.85-1.09) 1.17 (1.09-1.25) 1.05 (0.97-1.14)
HIV-1 Subtype, Non-B vs. B 0.48 (0.40-0.56) 0.79 (0.65-0.97) 0.58 (0.44-0.77) 0.80 (0.56-1.15) 0.48 (0.38-.59) 0.83 (0.64-1.06)
Viral load
> 5 Log copies/ml - - - - - -
4 - 5 Log copies/ml 2.36 (2.04-2.73) 2.16 (1.83-2.55) 2.01 (1.56-2.58) 1.71 (1.23-2.35) 1.83 (1.54-2.17) 1.68 (1.38-2.04)
< 4 Log copies/ml 2.92 (2.54-3.36) 3.06 (2.59-3.61) 3.22 (2.51-4.13) 2.61 (1.89-3.60) 1.60 (1.36-1.89) 1.70 (1.40-2.07)
CD4 cell count
>350 cells/mmc - - - - - -
200 – 350 cells/mmc 0.65 (0.58-0.74) 0.90 (0.78-1.03) 1.04 (0.85-1.27) 1.07 (0.84-1.36) 0.90 (0.78-1.04) 0.86 (0.73-1.01)
< 200 cells/mmc 0.82 (0.72-0.93) 0.87 (0.75-1.01) 1.01 (0.81-1.25) 1.36 (1.02-1.80) 0.83 (0.72-0.96) 0.88 (0.66-1.12)
Previous virological failure(s) 4.41 (3.84-5.07) 2.07 (1.74-2.47) 4.52 (3.63-5.63) 2.95 (2.17-3.99) 3.88 (3.17-4.75) 1.40 (1.10-1.78)
Prior ARV regimens, per 1 higher 1.16 (1.15-1.18) 1.11 (1.09-1.13) 1.14 (1.11-1.17) 1.03 (0.99-1.07) 1.21 (1.18-1.24) 1.13 (1.11-1.15)
Prior suboptimal NRTI therapy 3.45 (2.85-4.17) 1.50 (1.29-1.74) 2.52 (2.11-3.00) 1.04 (0.80-1.35) 3.16 (2.80-3.57) 1.27 (1.07-1.50)
Antiretrovira regimen in use - - - -
NNRTI + NRTIs - -
Boosted PI + NRTIs 0.95 (0.85-1.06) 0.65 (0.56-0.74)
Unboosted PI + NRTIs 0.84 (0.73-0.98) 0.75 (0.63-0.90)
PI + NNRTI + NRTI 3.51 (2.66-4.65) 1.87 (1.25-2.78)
Boosted vs unboosted PI - - - - 1.00 (0.88-1.15) 1.06 (0.90-1.23)
Study period, per 1 period higher 0.56 (0.53-0.59) 0.58 (0.54-0.61) 0.65 (0.59-0.71) 0.74 (0.66-0.82) 0.58 (0.55-0.62) 0.58 (0.54-0.62)
A logistic regression model was performed in subjects failing a combined antiretroviral treatment according to antiretrovirals in use at genotype.
aNucleoside reverse-transcriptase inhibitors.
bNon nucleoside reverse-transcriptase inhibitors.
cProtease inhibitors.
dOther: professional risk, transfusions¸ vertical transmission.
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served in female subjects [26,27].
Lower drug resistance rates were associated with plasma
HIV-1 viremia above 100,000 copies/ml. This finding is
different from previous observations obtained from the
ARCA database [17] and it is in agreement with findings
in patients undergoing resistance testing in routine clinical
practice [28]. This may be due to cases of very low adher-
ence, when low drug levels reduce both the efficacy of
antiretroviral therapy and emergence of resistant strains
[27]. Our observation underlines the need of genotypic
testing at the very early detection of virological failure,
when the HIV-1 viremia is still at a low level, as suggested
by recent guidelines [19].As expected, the occurrence of a previous virological fail-
ure increased the risk of resistance to any antiretroviral
class. Other treatment history features, such as the number
of cART regimens, have shown a role in the emergence of
class resistance to NRTIs and PIs, but not to NNRTIs. The
fact that NNRTI resistance shown no association with the
temporal length of antiretroviral treatment can be ex-
plained by the characteristic pattern of resistance evolution
of this antiretroviral class, whose use can be compromised
by a single substitution leading to cross resistance [29].
The risk of resistance to NRTIs was higher when the pa-
tients failed NNRTI rather than PI based treatments. This
is in agreement with previous findings and confirms that a
higher protection against NRTI resistance is obtained by
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genetic barrier [17,18,20]. However, this protection against
the emergence of NRTI resistance was observed either for
boosted or unboosted PIs compared to NNRTIs when the
entire time period of the study was considered. Similarly,
no difference in risk of PI mutations evolution could be
found when comparing boosted and unboosted PIs over-
time. Enven though unexpected, these observations are in
agreement with data demonstrating that comparable viro-
logical outcome was achieved when the same PI, boosted
or unboosted, was used in antiretroviral regimens in spe-
cific clinical settings and when allowed by guidelines
[30,31].
Interestingly, M184V and NNRTI resistance were less
common in subjects failing regimens including emtricita-
bine rather than lamivudine, as observed by previous stud-
ies [32]. This finding may be also partly related to the
availability and increasing use of fixed dose combinations
containing FTC, which have been shown to implement
adherence [33,34]. Nevertheless, no significant impact on
NNRTI resistance was observed when considering the
concomitant use of specific NRTI backbones (3TC vs.
FTC) or NNRTIs (EFV vs. FTC) in the multivariate model.
Of note, TA-sparing regimens did not appear to decrease
the risk of resistance. Even though the virological efficacy
of TAs is generally confirmed in several clinical settings
[35], our finding does not reduce the usefulness and viro-
logical efficacy of TA sparing compounds. In fact, our data
show a continuous drop in resistance prevalence in the
Italian HIV-infected population during a period when TA-
sparing regimens substantially substitute TA-including
combinations, mainly due to toxicity issues.
Some limitations of our work should be acknowledged.
First of all, Italian data on precise extent of HIV-1- treated
population, specific treatment prescriptions and related
overall achievement of virological suppression on cART
are not available at present. In fact, an increase of treat-
ment effectiveness could explain both the reduction of the
available resistance testing and the extent of resistance to
antiretrovirals. Moreover, we were not able to consider the
impact of self-reported adherence in our study population,
due to the lack of information regarding this issue for a
large number of patients, referring to several clinical cen-
ters in Italy. Furthermore, patients with resistant strains in
early years of the study could have been lost at follow-up,
due to several reasons including death, contributing to the
decline of overall resistance. As guidelines prescribe to
perform a genotypic resistance testing at failure, almost all
patients failing an antiretroviral regimens have been in-
cluded in the analysis. Nevertheless, the full information
about the number of subjects failing antiretroviral regi-
mens is not available, and we cannot exclude a partial loss
of information regarding subjects who were not tested for
antiretroviral resistance.Even though it was not possible to evaluate all the data
regarding the antiretroviral history of patients, our analysis
included main covariates such as previous virological fail-
ures, number of previous antiretroviral regimens, prior ex-
posure to suboptimal NRTI therapy. Importantly, this work
includes an evaluation of resistance according to the anti-
retroviral regimen in use at failure, representing an achieve-
ment in the analysis of acquired resistance not performed
in previous works [17,18,21].
In spite of the limitations mainly due to its retrospective
and multicenter design, our study shows a substantial de-
crease in drug resistance after stratification for antiretroviral
class in use at failure. This finding is encouraging for the
goal of a more effective treatment of the HIV infected
population, in order to achieve a stable reduction of the po-
tential virus transmitters. Moreover, the reduction we ob-
served in resistance prevalence among treated individuals is
probably the main driving factor leading to the observed re-
duction in primary resistance in our country [36].
Conclusion
In conclusion, our analysis shows a reduction of drug re-
sistance overtime, even when correcting for several other
or covariates or confounders. This is likely the conse-
quence of time-associated factors including the availability
of new potent drugs, updated guidelines for the treatment
of HIV infection, the availability and frequent use of resist-
ance testing to select for the optimal antiretroviral treat-
ment at baseline and whenever a virological failure occurs.
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